We have released 13th Oct’23: Special situation opportunity on the proposed open offer and promoter change in Glenmark Lifesciences. The same has also been produced below. For details and other updates, please log into the website at the following link – http://katalystwealth.com/index.php/my-account/
Note: For any queries, mail us at [email protected]
Date: 13th Oct’23
CMP – 650.00 (BSE); 650.25 (NSE)
Rating – Positive – 4% weightage; this is not an investment advice (refer rating interpretation at the end)
Glenmark Lifesciences (NSE – GLS)
Glenmark Lifesciences (GLS) is currently a subsidiary of Glenmark Pharmaceuticals Ltd (GPL) wherein GPL holds 82.67% stake in GLS.
GLS manufactures Generic APIs in therapy areas such as cardiovascular, central nervous system, pain management and diabetes. The company also provides CDMO services to a range of multinational and specialty pharmaceutical companies.
Generic APIs accounted for 92% of the sales of the company in FY 23 and the rest came from CDMO.
In terms of geographical mix, regulated markets account for 75% + sales of the company and the remaining comes from emerging markets.
Proposed change in ownership
As mentioned above, GPL is the current promoter of the company with 82.67% stake.
On 21st Sep’23, the company informed the exchanges that GPL has entered into a definitive agreement with Nirma Ltd for sale of its 74.84% stake in GLS at Rs 615/- per share.
Post transaction, GPL would be left with 7.83% stake in the company.
Further, because of share purchase agreement, Nirma has announced a mandatory open offer to acquire 17.33% stake in the company from the public shareholders at Rs 631.20/- per share.
The open offer includes the entire public shareholding in the company.
Rationale for the opportunity
We see this open offer and ownership change opportunity in GLS as the one with a known low downside and an unknown upside.
The rationale is as follows:
- The tentative schedule for the tendering period is 16th-30th Nov’23. As the open offer is for the entire public shareholding, at least during the tendering period one can tender shares at Rs 631.20/- with 100% acceptance and limit the downside in case of a fall.
- A lot of times new promoters bring in renewed focus and energy to distressed or slow growth companies resulting in stronger growth and re-rating.
|Particulars (in cr.)
|Operating Profit %
- Operationally, GLS has been performing well, is debt free with surplus cash of around Rs 300 crore + at the end of Jun’23 and the management has guided mid-teens growth with stable margins in FY 24.
- The valuations of the company seem reasonable at around 16 times trailing 12 months earnings.
The company has announced an interim dividend of Rs 22.50/- per share with 17th Oct’23 as the ex-date.
Since mid of Jul’23, the stock has been consolidating in the 600-650 odd range. As mentioned above, we see it as a low downside opportunity with an unknown upside.
However, to limit the downside, we will consider closing the opportunity in case of a fall below 600 odd levels (post the closure of the tendering period).
Over the past few months there’s been a significant rise in small cap index and small cap stocks. In case of a major correction, stocks across the board will get de-rated and can impact the valuations of Glenmark Lifesciences.
Acquirers have the right to withdraw the offer in case the statutory approvals are refused or the terms of conditions of the SPA are not met.
US-FDA audit for the company’s plants is due. In case of an adverse outcome, company’s sales and profits might get impacted.
Disclosure: I do not have any holding in Glenmark Lifesciences.
Positive – Expected return of ~15% + on annualized basis in medium to long term for investment recommendations and in short term for Special situations
Neutral – Expected Absolute return in the range of +/- 15%
Negative – Expected Absolute return of over -15%
Coverage closure – No further update on the stock
% weightage – allocation in the subject stock with respect to equity investments
Short term – Less than 1 year
Medium term – Greater than 1 year and less than 3 years
Long term – Greater than 3 years
Research Analyst Details
Name: Ekansh Mittal Email Id: [email protected] Ph: +91 727 5050062
Analyst ownership of the stock: No
Details of Associates: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
Disclaimer: www.katalystwealth.com (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to investors on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690
Address – 7, Panch Ratan, 7/128, Swaroop Nagar, Kanpur – 208002, Contact No. – +91-7275050062
Compliance Officer – Mr. Ekansh Mittal, +91-9818866676, [email protected]
Grievance Redressal – Mittal Consulting, [email protected], +91-9818866676, +91-7275050062
“Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.
Performance numbers do not include the impact of transaction fee and other related costs. Past performance does not guarantee future returns.
“Investment in securities market are subject to market risks. Read all the related documents carefully before investing.”
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision
A graph of daily closing prices of securities is available at www.bseindia.com (Choose a company from the list on the browser and select the “three years” period in the price chart
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Disclosure (SEBI RA Regulations)
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – No
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No